About Diagnos (TSE:ADK)
AdCare Health Systems, Inc., through its subsidiaries, is a self-managed real estate investment company that invests in real estate purposed for long-term care and senior living. The Company's business principally consists of leasing and subleasing such facilities to third-party tenants, which operate the facilities. The Company owns, leases, or manages for third parties approximately 40 facilities mainly in the Southeast. Its portfolio consists of over 30 skilled nursing facilities, approximately two assisted living facilities and an independent living facility. The Company's facilities provide a range of healthcare and related services to patients and residents, including skilled nursing and assisted living services, social services, various therapy services, and other rehabilitative and healthcare services for both long-term and short-stay patients and residents.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Home Healthcare Services
- Sub-Industry: N/A
- Symbol: TSE:ADK
- CUSIP: N/A
- Web: www.adcarehealth.com
- Trailing P/E Ratio: N/A
- P/E Growth: N/A
- Net Margins: 9.90%
- Return on Assets: 2.31%
Frequently Asked Questions for Diagnos (TSE:ADK)
What is Diagnos' stock symbol?
Diagnos trades on the Tornton Stock Exchange (TSX) under the ticker symbol "ADK."
Who are some of Diagnos' key competitors?
Some companies that are related to Diagnos include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Hospira (HSP), Teva Pharmaceutical Industries Ltd (TEVA), Smith & Nephew plc (SN), Omnicare (OCR), VCA (WOOF), NMC Health PLC (NMC), Valeant Pharmaceuticals Intl (VRX), Catalent (CTLT), Health Net (HNT), Patheon NV (PTHN), Mediclinic International PLC (MDC), Puma Biotechnology (PBYI), Alere (ALR) and ConvaTec Group PLC (CTEC).
Who are Diagnos' key executives?
Diagnos' management team includes the folowing people:
- Allan J. Rimland, President, Chief Executive Officer, Chief Financial Officer, Director
- E. Clinton Cain, Senior Vice President, Chief Accounting Officer, Controller
- Krishna R. Polu M.D., Chief Medical Officer
- Michael J. Fox, Lead Independent Director
- David A. Tenwick, Director
- John Laurence Clare III, Independent Director
- Thomas W. Knaup, Independent Director
- Brian M. Szames, Independent Director
How do I buy Diagnos stock?
MarketBeat Community Rating for Diagnos (TSE ADK)MarketBeat's community ratings are surveys of what our community members think about Diagnos and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shares of Diagnos and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
Consensus Ratings for Diagnos (TSE:ADK) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Diagnos (TSE:ADK)
Analysts' Ratings History for Diagnos (TSE:ADK)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Diagnos (TSE:ADK)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Diagnos (TSE:ADK)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Diagnos (TSE:ADK)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Diagnos (TSE:ADK)Insider Trades by Quarter for Diagnos (TSE:ADK)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/3/2017||Georges Lawrence Hébert||Director||Buy||200,000||C$0.16||C$32,000.00|
Headline Trends for Diagnos (TSE:ADK)
Latest Headlines for Diagnos (TSE:ADK)
Diagnos (ADK) Chart for Wednesday, October, 18, 2017